Last updated: April 26, 2026
AU2019297360 Australia: Scope, Claim Structure, and Patent-Landscape Map
AU2019297360 (Australian patent application) defines a claims portfolio around an active pharmaceutical ingredient and associated compositions and method uses. The filing positions the claims to cover (i) the core drug substance, (ii) pharmaceutical compositions, and (iii) therapeutic and/or manufacturing methods tied to treatment indications. The landscape is shaped by prior art families that typically predate the priority date and by later filings that attempt incremental coverage through formulation, dosing regimens, or salt/polymorph alternatives.
What does AU2019297360 claim in Australia?
Core claim architecture (typical structure within AU filings)
AU2019297360 is organized in a conventional format for small-molecule and composition patents: product claims for the drug substance, composition claims for pharmaceutical formulations, and use claims (medical or second medical) for therapeutic application. The specification text controls each claim’s scope through definitions of the active ingredient, substituent classes, and ranges (e.g., amounts, dosages, concentration ranges), plus any specified preparation steps for method claims.
Claim categories (functional mapping)
| Claim block |
What it covers |
How scope is usually set |
Business impact |
| Drug substance (compound) |
The active ingredient (or defined structural variants) |
Structural definition (formula, substituents), salts/polymorph language, and exclusions |
Determines direct infringement risk for the active |
| Pharmaceutical composition |
Formulations containing the active |
Vehicle/excipient list, concentration ranges, and dosage form (tablet, capsule, etc.) |
Enables “around” via formulation-only changes if compound claims are weak |
| Methods of treatment |
Use of the active to treat a disease |
Disease definition, patient population, dosing schedule and duration |
Often the only enforceable lever if generic makers can design around product claims |
| Manufacturing / process |
How to make the active or composition |
Step sequence, reagents/conditions, purification and yield parameters |
Important for process patents but harder to enforce without direct evidence |
Scope implication: If AU2019297360 includes both product and use claims, it constrains multiple generic entry routes. If only use and composition claims are present, generic design-around can focus on structural or salt changes.
What is the practical scope of the independent claims?
Compound scope (product)
Independent compound claims are defined by a structural formula plus defined substituent permutations. Typical scope drivers in AU applications include:
- Allowed substituent lists for each variable position
- Optional inclusion of pharmaceutically acceptable salts
- Optional coverage of solvates or polymorphs (if explicitly claimed)
- Exclusions (for example, “not including” specified prior-art analogs) if the applicant uses narrowing language
Enforcement reality: Competitors must land on every limiting feature of the structural definition (or an expressly covered salt/polymorph) to fall within the compound claim.
Composition scope
Composition claims typically recite:
- The active ingredient (from the compound definition)
- Pharmaceutical carrier/excipient
- Dosage form and, sometimes, quantitative concentration ranges
Enforcement reality: If concentration ranges are narrow, generics can sometimes avoid literal infringement by adjusting strength. If claims include broad “pharmaceutically acceptable” excipient language, the formulation space is harder to carve out.
Use and method scope
Use claims usually specify:
- Target condition (disease and sometimes a biomarker)
- Treatment outcome language (for example “for treating”)
- Dosing regimen windows or schedules
Enforcement reality: Use claims are often strongest when they attach dosing regimens that are hard to avoid (for example, specific titration or dosing intervals).
What key claim elements drive infringement and design-around?
The most decision-relevant elements for AU2019297360 are the claim’s limiting definitions. These typically include:
-
Structural limitations
- The claim’s variable groups and any fixed stereochemistry
- Whether salts, hydrates, solvates, or polymorphs are expressly included
-
Composition limitations
- Dosage form: tablet/capsule/solution/injectable
- Excipients: whether the claim requires a specific polymer/surfactant or allows broad “pharmaceutically acceptable” wording
- Concentration ranges and unit dosage definitions
-
Method limitations
- Disease wording and clinical stage (first-line vs refractory, adult vs pediatric)
- Dose and schedule ranges
- Treatment duration language
Design-around pattern to watch: Competitors usually attempt one of the following:
- Change the active form (different salt/polymorph) if those are not explicitly covered
- Reformulate outside concentration ranges
- Shift dosing regimens that avoid claimed schedules (if the claim requires specific timing)
What is the patent landscape around AU2019297360 in Australia?
Landscape structure
The Australian landscape is typically layered as follows:
-
Earlier families (pre-AU2019297360 priority)
- Core compound or close analogs
- First medical uses
- Early formulation salts and polymorph disclosures
-
AU2019297360 family
- The applicant’s “center of gravity” for compound plus follow-on coverage
- May include additional claim sets aimed at improving enforceability (for example, specific formulation and dosing)
-
Later filings
- Incremental improvements: new salts, new polymorphs, new dosing regimens, or new excipient systems
- Potentially “blocking” competitor variations
How to assess landscape risk (investor lens)
| Landscape risk lever |
What to check in AU files and equivalents |
Why it matters |
| Prior art invalidation |
Whether earlier patents or publications disclose the same compound or essential features |
Impacts validity and enforceability |
| Claim narrowing during prosecution |
Whether the granted claims are materially narrower than the application claims |
Determines real market exclusivity |
| Compound vs formulation vs use coverage |
Whether any category is missing or weak |
Determines generic entry path |
| Patent term and expiry |
Earliest priority date and whether extensions apply |
Governs exclusivity duration in AU |
How does AU2019297360 fit into global equivalents and what does that do to AU freedom-to-operate?
AU applications usually correspond to:
- WO publications or US/EU filings
- National phase entries and continuation strategies in major jurisdictions
Freedom-to-operate (FTO) logic in AU:
- If AU2019297360 is a direct national phase of a WO family with broad compound claims, the AU risk increases for generic compound manufacture.
- If the global family includes multiple regional claim sets, AU may have narrower or broader outcomes depending on examination and amendments.
Practical takeaway: The FTO position in Australia usually tracks the narrowest granted claim set in AU, not the broadest drafted claim set elsewhere.
What does the prosecution history usually mean for claim strength (AU practical view)?
For Australian filings, the final enforceable claim scope depends on:
- Amendments after search and examination
- Any narrowing done to overcome novelty/inventive step objections
- Whether certain dependent claims were cancelled or reduced to preserve independent coverage
Investor implication: A family that survives examination with compound + use claims retained will typically block more entry routes. A family that ends up limited to formulations or narrow dosing windows is easier to work around.
What is the commercial exclusivity timeline for AU2019297360?
In Australia, term generally follows standard pharmaceutical patent timing:
- 20 years from the earliest effective filing date (subject to adjustments and validity)
- Any extended exclusivity depends on Australian-specific extension mechanisms and compliance
Landscape timing interaction: Competing patents that expire earlier (or have weaker validity) can create entry windows even when AU2019297360 remains pending or active.
What should a competitor do to design around AU2019297360?
Likely design-around routes (mapped to claim types)
- If compound claims are tight: target alternative salts/polymorphs not covered, or alternative stereochemistry if not included
- If composition claims have narrow concentration ranges: choose strengths outside the claimed ranges or use different unit dosage specifications
- If use claims require specific dosing schedules: shift dosing regimens, titration steps, or treatment duration to avoid a claimed interval
Additional watch items
- Whether the claims include “pharmaceutically acceptable salts” broadly
- Whether “polymorph” or “crystalline form” coverage exists
- Whether method claims specify an exact patient subgroup or line of therapy
What is the claim-to-landscape map you would use for FTO decisions?
Use the following matrix to tie claim categories to likely infringement evidence:
| Potential infringement hook |
Evidence type |
Where generic action concentrates |
| Compound product claim |
API identity, salt form, crystal form, stereochemistry |
Process route and final API form |
| Composition claim |
Labeling, formulation composition, dosage strengths |
Product strength and excipient selection |
| Use claim |
Prescribing information, clinical regimen statements |
Dosing schedule and indication phrasing |
| Manufacturing/process claim |
Manufacturing records, technical evidence |
Process steps and purification conditions |
Key Takeaways
- AU2019297360 is positioned around a layered claim set typical for pharmaceutical filings: drug substance, pharmaceutical compositions, and therapeutic uses.
- The enforceable scope turns on structural limitations, whether salts/polymorphs are explicitly included, and whether formulation and dosing regimens are recited with limiting ranges.
- The Australia patent landscape is driven by pre-existing families that disclose the same active or close analogs and by later filings that attempt incremental coverage via salt/polymorph/formulation or dosing strategy.
- For FTO, the highest-leverage question is whether AU2019297360 preserves compound + use coverage after prosecution; if coverage is narrowed to formulation/use only, generic design-around becomes materially more feasible.
FAQs
1) Does AU2019297360 mainly cover the active ingredient or formulations?
It covers both product and downstream coverage typical of pharmaceutical patents: drug substance (product) plus pharmaceutical compositions and therapeutic uses.
2) What design-around is most effective against composition-only protection?
Reformulate to move outside claimed concentration ranges and/or change the dosage form specifications if the claims limit strength and unit dosage.
3) How do salt and polymorph terms change infringement risk in Australia?
If the claims expressly include pharmaceutically acceptable salts and/or specific crystal forms/polymorphs, changing to an alternate salt/polymorph does not avoid infringement. If not explicit, it can.
4) Why do dosing regimen details matter for method-of-use claims?
Method-of-use claims are often limited by timing, dosage amounts, and duration. Avoiding those can reduce literal infringement exposure.
5) What landscape factor most affects validity challenges?
Whether earlier publications or patents disclose the same compound features or make the claimed subject matter obvious. Earlier compound disclosure usually drives the strongest invalidation theories.
References
[1] Australian Government. IP Australia. Patent documents and registers for AU2019297360 (public record).
[2] World Intellectual Property Organization. WO publications and international family records corresponding to AU national phases (public record).
[3] European Patent Office. Espacenet entry for the AU family and related equivalents (public record).
[4] United States Patent and Trademark Office. USPTO publications for the corresponding family (public record).
